MeiraGTx (MGTX) Projected to Post Earnings on Thursday

MeiraGTx (NASDAQ:MGTX) is expected to be releasing its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect MeiraGTx to post earnings of ($0.4583) per share and revenue of $0.70 million for the quarter. Interested persons may review the information on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Friday, August 21, 2026 at 9:30 AM ET.

MeiraGTx (NASDAQ:MGTX) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.57) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.04. The firm had revenue of $0.29 million for the quarter, compared to analyst estimates of $17.00 million. On average, analysts expect MeiraGTx to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

MeiraGTx Stock Performance

Shares of NASDAQ:MGTX opened at $13.02 on Tuesday. The company has a market cap of $1.21 billion, a PE ratio of -8.80 and a beta of 1.23. MeiraGTx has a 52 week low of $6.62 and a 52 week high of $15.35. The firm has a 50 day simple moving average of $11.79 and a 200 day simple moving average of $9.69.

Analyst Upgrades and Downgrades

MGTX has been the subject of a number of research analyst reports. Royal Bank Of Canada increased their target price on MeiraGTx from $25.00 to $26.00 and gave the company an “outperform” rating in a report on Wednesday, July 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of MeiraGTx in a research note on Friday, July 17th. HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of MeiraGTx in a report on Wednesday, July 8th. Finally, Piper Sandler boosted their target price on MeiraGTx from $26.00 to $30.00 and gave the stock an “overweight” rating in a report on Wednesday, April 22nd. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $26.00.

Insider Buying and Selling at MeiraGTx

In other MeiraGTx news, CEO Alexandria Forbes sold 62,000 shares of the stock in a transaction on Tuesday, May 19th. The stock was sold at an average price of $9.17, for a total transaction of $568,540.00. Following the completion of the transaction, the chief executive officer directly owned 1,387,695 shares in the company, valued at $12,725,163.15. This represents a 4.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Richard Giroux sold 56,000 shares of the company’s stock in a transaction dated Tuesday, July 21st. The stock was sold at an average price of $12.51, for a total transaction of $700,560.00. Following the sale, the chief financial officer directly owned 908,530 shares in the company, valued at $11,365,710.30. This represents a 5.81% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 145,659 shares of company stock worth $1,678,453 over the last three months. Company insiders own 7.40% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets increased its stake in shares of MeiraGTx by 43.8% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,810 shares of the company’s stock valued at $31,000 after acquiring an additional 1,466 shares during the last quarter. Kennedy Capital Management LLC boosted its stake in MeiraGTx by 2.2% during the 4th quarter. Kennedy Capital Management LLC now owns 70,738 shares of the company’s stock worth $562,000 after acquiring an additional 1,495 shares during the last quarter. Russell Investments Group Ltd. grew its holdings in MeiraGTx by 4.3% during the third quarter. Russell Investments Group Ltd. now owns 82,844 shares of the company’s stock valued at $682,000 after purchasing an additional 3,452 shares during the period. XTX Topco Ltd grew its holdings in MeiraGTx by 11.0% during the fourth quarter. XTX Topco Ltd now owns 38,030 shares of the company’s stock valued at $302,000 after purchasing an additional 3,766 shares during the period. Finally, Hsbc Holdings PLC grew its holdings in MeiraGTx by 24.3% during the fourth quarter. Hsbc Holdings PLC now owns 23,792 shares of the company’s stock valued at $189,000 after purchasing an additional 4,649 shares during the period. 67.48% of the stock is currently owned by institutional investors and hedge funds.

About MeiraGTx

MeiraGTx Holdings plc is a clinical-stage biotechnology company dedicated to developing gene therapies for the treatment of rare diseases. Founded in 2014 as an outgrowth of research at University College London, the company focuses on leveraging adeno-associated virus (AAV) vectors to deliver functional genes to target tissues. MeiraGTx’s pipeline spans ocular, central nervous system and systemic indications, addressing conditions such as inherited retinal dystrophies and neurodegenerative disorders that currently lack effective therapies.

The company’s lead programs include AAV-based candidates designed to restore or replace defective genes underlying rare retinal diseases and to modulate cellular pathways in neurological disorders.